Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

96
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
96
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

56
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
56

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies.

Frontiers in pharmacology·2026
Same author

Persistent left atrial mechanical dysfunction and long-term risk in Takotsubo syndrome.

International journal of cardiology·2026
Same author

Diaphragm-specific effects of L-citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy.

British journal of pharmacology·2026
Same author

[Ten questions about cardiac sarcoidosis].

Giornale italiano di cardiologia (2006)·2026
Same author

Demographic and training variations across cardiology subspecialties in Italy: a national survey.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Improved endothelial function in heart failure outpatients with reduced ejection fraction after vericiguat therapy.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026

Related Experiment Video

Updated: Jun 4, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.1K

Biomarker profiles that differentiate type-1 and type 2 myocardial infarction.

Marco Mele1, Francesco Mautone2, Ilaria Ragnatela2

  • 1Cardiothoracic Department, Policlinico Riuniti Foggia, Foggia Italy.

Heart & Lung : the Journal of Critical Care
|January 3, 2025
PubMed
Summary

Distinguishing type-1 myocardial infarction (T1MI) from type-2 myocardial infarction (T2MI) is crucial. Biomarker profiles, particularly the high-sensitivity troponin I (hs-cTnI) to procalcitonin (PCT) ratio, can effectively differentiate T1MI from T2MI in non-ST-elevation myocardial infarction (NSTEMI) patients.

Keywords:
BiomarkersNon-ischemic acute myocardial injuryType-2 Myocardial Infarction

More Related Videos

Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.5K
Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
08:38

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery

Published on: August 16, 2019

27.5K

Related Experiment Videos

Last Updated: Jun 4, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.1K
Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.5K
Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
08:38

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery

Published on: August 16, 2019

27.5K

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Acute Cardiac Care

Background:

  • Accurate differentiation between type-1 myocardial infarction (T1MI) and type-2 myocardial infarction (T2MI) is essential upon patient admission and during hospitalization.
  • Misclassification can lead to unnecessary invasive procedures and inappropriate admissions to acute cardiac care units.
  • Establishing a simple diagnostic profile using readily available biomarkers can improve clinical decision-making.

Purpose of the Study:

  • To define a simple biomarker profile for differentiating T1MI from T2MI.
  • To assess the utility of commonly used biomarkers in distinguishing these myocardial infarction types.
  • To identify predictors for T1MI in patients presenting with non-ST-elevation acute myocardial infarction (NSTEMI).

Main Methods:

  • Prospective observational study of 213 consecutive patients with provisional NSTEMI diagnosis.
  • Final diagnosis of T1MI, T2MI, or non-ischemic acute myocardial injury (NAMI) based on clinical and instrumental findings.
  • Assessment of high-sensitivity Troponin I (hs-cTnI), CK-MB, C-reactive protein (CRP), procalcitonin (PCT), and NT-proBNP.

Main Results:

  • Hs-cTnI peak/PCT ratio and hs-cTnI peak/NT-proBNP ratio significantly differentiated T1MI from T2MI and T2MI + NAMI.
  • Hs-cTnI peak/PCT ratio was identified as a predictor of T1MI (OR 1.03, 95% CI 1.01-1.06, p < 0.05) with 0.704 accuracy.
  • No significant differences were detected between T2MI and NAMI groups.

Conclusions:

  • The admission biomarker profile, particularly hs-cTnI ratios with PCT and NT-proBNP, can differentiate T1MI from T2MI in NSTEMI patients.
  • This biomarker profile aids in avoiding unnecessary invasive exams and optimizing acute cardiac care unit admissions.